Development of novel nanoliposomes co-loaded with ROR1 inhibitor and Ce6 for the treatment of EGFR-TKIs resistant NSCLC by synergistic targeted inhibitor therapy and photodynamic therapy
{{output}}
Currently, developing effective treatments for epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) resistant non-small cell lung cancer (NSCLC) is one of the main research focuses in the field. Receptor tyrosine kinase-like orphan receptor ... ...
